-+ 0.00%
-+ 0.00%
-+ 0.00%

FIRST PATIENT DOSED IN SAB BIO’S SAFEGUARD CLINICAL TRIAL OF SAB-142 FOR THE TREATMENT OF STAGE 3 T1D

Reuters·12/18/2025 13:00:01

Please log in to view news